Phenotypic Overlap of Lethal Arrhythmias Associated with Cardiac Sodium Mutations: Individual-Specific or Mutation-Specific?

Chapter

Abstract

Mutations in cardiac sodium channel gene SCN5A are responsible for a spectrum of hereditary arrhythmias including type-3 long QT syndrome (LQT3), Brugada syndrome (BrS), conduction disturbance, and sinus node dysfunction. These syndromes were originally regarded as independent entities with distinct clinical manifestations and biophysical properties. However, recent evidence shows considerable clinical overlap among these disorders, implicating a new disease entity referred to as an overlap syndrome of cardiac sodium channelopathy. Class IC sodium channel blockers often induce BrS phenotype in some patients with LQT3. Furthermore, recent genetic studies have revealed that E1784K is the most prevalent SCN5A mutation responsible not only for LQT3 but BrS, confirming the clinical and genetic overlap of LQT3 and BrS. Here I show evidence that the clinical manifestations of SCN5A mutations are most probably determined by the biophysical and pharmacological properties of the mutations. I also provide an overview of current knowledge on the clinical features, prevalence, and molecular and biophysical mechanisms underlying the overlap syndrome to gain more insight into this complex issue and generate better therapeutic strategies for patient management.

Keywords

Brugada syndrome flecainide long QT syndrome overlap syndrome SCN5A 

References

  1. 1.
    Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron. 2000;26:13–25.PubMedCrossRefGoogle Scholar
  2. 2.
    George Jr AL. Inherited disorders of voltage-gated sodium channels. J Clin Invest. 2005;115:1990–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Bennett PB, Yazawa K, Makita N, et al. Molecular mechanism for an inherited cardiac arrhythmia. Nature. 1995;376:683–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Makita N, Horie M, Nakamura T, et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation. 2002;106:1269–74.PubMedCrossRefGoogle Scholar
  5. 5.
    Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998;392:293–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Schott JJ, Alshinawi C, Kyndt F, et al. Cardiac conduction defects associate with mutations in SCN5A. Nat Genet. 1999;23:20–1.PubMedCrossRefGoogle Scholar
  7. 7.
    Benson DW, Wang DW, Dyment M, et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest. 2003;112:1019–28.PubMedGoogle Scholar
  8. 8.
    Groenewegen WA, Firouzi M, Bezzina CR, et al. A cardiac sodium channel mutation cosegregates with a rare connexin40 genotype in familial atrial standstill. Circ Res. 2003;92:14–22.PubMedCrossRefGoogle Scholar
  9. 9.
    Makita N, Sasaki K, Groenewegen WA, et al. Congenital atrial standstill associated with coinheritance of a novel SCN5A mutation and connexin 40 polymorphisms. Heart Rhythm. 2005;2:1128–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Takehara N, Makita N, Kawabe J, et al. A cardiac sodium channel mutation identified in Brugada syndrome associated with atrial standstill. J Intern Med. 2004;255:137–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Wang DW, Viswanathan PC, Balser JR, et al. Clinical, genetic, and biophysical characterization of SCN5A mutations associated with atrioventricular conduction block. Circulation. 2002;105:341–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Wang DW, Desai RR, Crotti L, et al. Cardiac sodium channel dysfunction in sudden infant death syndrome. Circulation. 2007;115:368–76.PubMedCrossRefGoogle Scholar
  13. 13.
    Otagiri T, Kijima K, Osawa M, et al. Cardiac ion channel gene mutations in sudden infant death syndrome. Pediatr Res. 2008;64:482–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Ackerman MJ, Siu BL, Sturner WQ, et al. Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. JAMA. 2001;286:2264–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Olson TM, Michels VV, Ballew JD, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA. 2005;293:447–54.PubMedCrossRefGoogle Scholar
  16. 16.
    Darbar D, Kannankeril PJ, Donahue BS, et al. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation. 2008;117:1927–35.PubMedCrossRefGoogle Scholar
  17. 17.
    Ge J, Sun A, Paajanen V, et al. Molecular and clinical characterization of a novel SCN5A mutation associated with atrioventricular block and dilated cardiomyopathy. Circ Arrhythm Electrophysiol. 2008;1:83–92.PubMedCrossRefGoogle Scholar
  18. 18.
    McNair WP, Ku L, Taylor MRG, et al. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation. 2004;110:2163–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Watanabe H, Koopmann TT, Le Scouarnec S, et al. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest. 2008;118:2260–8.PubMedGoogle Scholar
  20. 20.
    Keating MT. The long QT syndrome. A review of recent molecular genetic and physiologic discoveries. Medicine. 1996;75:1–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80:805–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995;92:3381–6.PubMedGoogle Scholar
  23. 23.
    Benhorin J, Taub R, Goldmit M, et al. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation. 2000;101:1698–706.PubMedGoogle Scholar
  24. 24.
    Schwartz PJ. The congenital long QT syndromes from genotype to phenotype: clinical implications. J Intern Med. 2006;259:39–47.PubMedCrossRefGoogle Scholar
  25. 25.
    Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992;20:1391–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J. 2002;23:1648–54.PubMedGoogle Scholar
  27. 27.
    Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol. 2001;12:268–72.PubMedCrossRefGoogle Scholar
  28. 28.
    Tan HL, Bink-Boelkens MT, Bezzina CR, et al. A sodium-channel mutation causes isolated cardiac conduction disease. Nature. 2001;409:1043–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Shirai N, Makita N, Sasaki K, et al. A mutant cardiac sodium channel with multiple biophysical defects associated with overlapping clinical features of Brugada syndrome and cardiac conduction disease. Cardiovasc Res. 2002;53:348–54.PubMedCrossRefGoogle Scholar
  30. 30.
    Makiyama T, Akao M, Tsuji K, et al. High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCN5A gene mutations. J Am Coll Cardiol. 2005;46:2100–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Priori SG, Napolitano C, Schwartz PJ, et al. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation. 2000;102:945–7.PubMedGoogle Scholar
  32. 32.
    Grant AO, Carboni MP, Neplioueva V, et al. Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. J Clin Invest. 2002;110:1201–9.PubMedGoogle Scholar
  33. 33.
    Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 2000;102:1178–85.PubMedGoogle Scholar
  34. 34.
    Priori SG, Napolitano C, Gasparini M, et al. Clinical and genetic heterogeneity of right bundle branch block and ST- segment elevation syndrome: a prospective evaluation of 52 families. Circulation. 2000;102:2509–15.PubMedGoogle Scholar
  35. 35.
    Shin DJ, Kim E, Park SB, et al. A novel mutation in the SCN5A gene is associated with Brugada syndrome. Life Sci. 2007;80:716–24.PubMedCrossRefGoogle Scholar
  36. 36.
    Juang JM, Huang SK, Tsai CT, et al. Characteristics of Chinese patients with symptomatic Brugada syndrome in Taiwan. Cardiology. 2003;99:182–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Zareba W, Sattari MN, Rosero S, et al. Altered atrial, atrioventricular, and ventricular conduction in patients with the long QT syndrome caused by the ΔKPQ SCN5A sodium channel gene mutation. Am J Cardiol. 2001;88:1311–14.PubMedCrossRefGoogle Scholar
  38. 38.
    Veldkamp MW, Viswanathan PC, Bezzina C, et al. Two distinct congenital arrhythmias evoked by a multidysfunctional Na+ channel. Circ Res. 2000;86:E91–977.PubMedGoogle Scholar
  39. 39.
    Bezzina C, Veldkamp MW, van Den Berg MP, et al. A single Na+ channel mutation causing both long-QT and Brugada syndromes. Circ Res. 1999;85:1206–13.PubMedGoogle Scholar
  40. 40.
    Wei J, Wang DW, Alings M, et al. Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. Circulation. 1999;99:3165–71.PubMedGoogle Scholar
  41. 41.
    Makita N, Behr E, Shimizu W, et al. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest. 2008;118:2219–29.PubMedGoogle Scholar
  42. 42.
    Shin DJ, Jang Y, Park HY, et al. Genetic analysis of the cardiac sodium channel gene SCN5A in Koreans with Brugada syndrome. J Hum Genet. 2004;49:573–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Chen T, Inoue M, Sheets MF. Reduced voltage dependence of inactivation in the SCN5A sodium channel mutation delF1617. Am J Physiol Heart Circ Physiol. 2005;288:H2666–267676.PubMedCrossRefGoogle Scholar
  44. 44.
    Smits JP, Koopmann TT, Wilders R, et al. A mutation in the human cardiac sodium channel (E161K) contributes to sick sinus syndrome, conduction disease and Brugada syndrome in two families. J Mol Cell Cardiol. 2005;38:969–81.PubMedCrossRefGoogle Scholar
  45. 45.
    Schulze-Bahr E, Eckardt L, Breithardt G, et al. Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat. 2003;21:651–2.PubMedCrossRefGoogle Scholar
  46. 46.
    Cordeiro JM, Barajas-Martinez H, Hong K, et al. Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada syndrome. Circulation. 2006;114:2026–33.PubMedCrossRefGoogle Scholar
  47. 47.
    Rossenbacker T, Carroll SJ, Liu H, et al. Novel pore mutation in SCN5A manifests as a spectrum of phenotypes ranging from atrial flutter, conduction disease, and Brugada syndrome to sudden cardiac death. Heart Rhythm. 2004;1:610–15.PubMedCrossRefGoogle Scholar
  48. 48.
    Itoh H, Shimizu M, Tanaka S, et al. A novel missense mutation in the SCN5A gene associated with Brugada syndrome bidirectionally affecting blocking actions of antiarrhythmic drugs. J Cardiovasc Electrophysiol. 2005;16:486–93.PubMedCrossRefGoogle Scholar
  49. 49.
    Potet F, Mabo P, Le Coq G, et al. Novel Brugada SCN5A mutation leading to ST segment elevation in the inferior or the right precordial leads. J Cardiovasc Electrophysiol. 2003;14:200–3.PubMedCrossRefGoogle Scholar
  50. 50.
    Smits JP, Eckardt L, Probst V, et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol. 2002;40:350–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation. 2001;104:3081–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Tan BH, Valdivia CR, Song C, et al. Partial expression defect for the SCN5A missense mutation G1406R depends upon splice variant background Q1077 and rescue by mexiletine. Am J Physiol Heart Circ Physiol. 2006;291:H1822–8.Google Scholar
  53. 53.
    Kehl HG, Haverkamp W, Rellensmann G, et al. Images in cardiovascular medicine. Life-threatening neonatal arrhythmia: successful treatment and confirmation of clinically suspected extreme long QT-syndrome-3. Circulation. 2004;109:e205–2066.PubMedCrossRefGoogle Scholar
  54. 54.
    Chang CC, Acharfi S, Wu MH, et al. A novel SCN5A mutation manifests as a malignant form of long QT syndrome with perinatal onset of tachycardia/bradycardia. Cardiovasc Res. 2004;64:268–78.PubMedCrossRefGoogle Scholar
  55. 55.
    Tester DJ, Will ML, Haglund CM, et al. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2005;2:507–17.PubMedCrossRefGoogle Scholar
  56. 56.
    Valdivia CR, Ackerman MJ, Tester DJ, et al. A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine. Cardiovasc Res. 2002;55:279–89.PubMedCrossRefGoogle Scholar
  57. 57.
    Ye B, Valdivia CR, Ackerman MJ, et al. A common human SCN5A polymorphism modifies expression of an arrhythmia causing mutation. Physiol Genomics. 2003;12:187–93.PubMedGoogle Scholar
  58. 58.
    Lupoglazoff JM, Cheav T, Baroudi G, et al. Homozygous SCN5A mutation in long-QT syndrome with functional two-to-one atrioventricular block. Circ Res. 2001;89:E16–2121.PubMedCrossRefGoogle Scholar
  59. 59.
    Tester DJ, Ackerman MJ. Genetic testing for cardiac channelopathies: ten questions regarding clinical ­considerations for heart rhythm allied professionals. Heart Rhythm. 2005;2:675–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Shim SH, Ito M, Maher T, et al. Gene sequencing in neonates and infants with the long QT syndrome. Genet Test. 2005;9:281–4.PubMedCrossRefGoogle Scholar
  61. 61.
    Viswanathan PC, Bezzina CR, George Jr AL, et al. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. Circulation. 2001;104:1200–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Moss AJ, Windle JR, Hall WJ, et al. Safety and efficacy of flecainide in subjects with long QT-3 syndrome (ΔKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol. 2005;10:59–66.PubMedCrossRefGoogle Scholar
  63. 63.
    Kapa S, Tester DJ, Salisbury BA, et al. Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. Circulation. 2009;120:1752–60.PubMedCrossRefGoogle Scholar
  64. 64.
    Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm. 2010;7:33–46.PubMedCrossRefGoogle Scholar
  65. 65.
    Veldkamp MW, Wilders R, Baartscheer A, et al. Contribution of sodium channel mutations to bradycardia and sinus node dysfunction in LQT3 families. Circ Res. 2003;92:976–83.PubMedCrossRefGoogle Scholar
  66. 66.
    Baroudi G, Chahine M. Biophysical phenotypes of SCN5A mutations causing long QT and Brugada syndromes. FEBS Lett. 2000;487:224–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Nagatomo T, January CT, Makielski JC. Preferential block of late sodium current in the LQT3 ΔKPQ mutant by the class IC antiarrhythmic flecainide. Mol Pharmacol. 2000;57:101–7.PubMedGoogle Scholar
  68. 68.
    Moss AJ, Zareba W, Benhorin J, et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation. 1995;92:2929–34.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Molecular PhysiologyNagasaki University Graduate School of Biomedical SciencesNagasakiJapan

Personalised recommendations